Hydralazine - Barbeau Pharma/PDL BioPharma

Drug Profile

Hydralazine - Barbeau Pharma/PDL BioPharma

Alternative Names: BPI-103

Latest Information Update: 10 Sep 2008

Price : $50

At a glance

  • Originator Barbeau Pharma
  • Class Antihypertensives; Heart failure therapies; Peripheral vasodilators; Phthalazines; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypertension in pregnancy

Highest Development Phases

  • No development reported Hypertension in pregnancy

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 10 Sep 2008 No development reported - Clinical-Phase-Unknown for Hypertension in pregnancy in USA (IV)
  • 20 Mar 2007 Clinical development is ongoing for Hypertension in pregnancy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top